A patient with advanced, treatment-resistant lung cancer achieved a tumor-free state after receiving the selenium compound selenite, according to a case report from researchers at Karolinska University Hospital and Karolinska Institutet. The report, published in the journal Oncology and Therapy, describes how the patient’s tumors disappeared following intravenous selenite therapy. While the results are striking, the authors emphasize that this is a single case and that further studies are needed to confirm the findings.

Key takeaways

  • A patient with advanced non-small cell lung cancer that had not responded to standard treatments became tumor-free after selenite therapy.
  • The treatment involved intravenous infusions of selenite, a selenium-based compound.
  • Imaging scans showed no detectable tumors after the treatment course.
  • The case report suggests selenite may work by inducing oxidative stress in cancer cells.
  • Researchers caution that this is a single case and not a clinical trial; more research is required.

Background on selenite and cancer

Selenite is an inorganic form of the essential trace element selenium. In laboratory studies, selenite has shown the ability to trigger cancer cell death through oxidative stress and other mechanisms. Unlike many conventional chemotherapies, selenite is thought to preferentially target cancer cells while sparing normal cells, at least in preclinical models. However, translating these effects to human patients has been challenging, and selenite is not currently approved as a cancer treatment.

Details of the case report

The patient in the report had advanced non-small cell lung cancer that had progressed despite multiple lines of standard therapy, including chemotherapy, immunotherapy, and targeted agents. Given the lack of options, the clinical team offered treatment with intravenous selenite under a compassionate use protocol. The patient received a series of infusions over several weeks. Follow-up imaging, including CT and PET scans, revealed that all previously visible tumors had disappeared. The patient remained tumor-free at the time of the report’s publication.

The researchers noted that the patient experienced some side effects, such as fatigue and transient changes in blood selenium levels, but these were manageable. The report does not specify the exact dosage or duration of treatment, but it states that the regimen was based on earlier preclinical and early-phase clinical data.

Implications and limitations

This case adds to a small but growing body of evidence that selenite may have anticancer activity in humans. The researchers from Karolinska suggest that the compound’s ability to generate reactive oxygen species could be responsible for killing tumor cells. However, they stress that a single case cannot prove effectiveness. The patient’s response may be due to unique biological factors, and selenite may not work in other patients. Randomized controlled trials are needed to determine whether selenite is a viable treatment for lung cancer or other malignancies.

Experts not involved in the report have also urged caution. While the outcome is encouraging, they point out that many promising case reports have not led to broader clinical success. Additionally, selenium compounds can be toxic at high doses, so careful dosing and monitoring are essential.

Frequently Asked Questions

What is selenite?

Selenite is an inorganic salt of selenium, a mineral that is essential in small amounts for human health. In higher doses, selenite can induce oxidative stress, which may selectively kill cancer cells. It is being investigated as a potential cancer therapy, but it is not yet approved for this use.

How was the patient in the case report treated?

The patient received intravenous infusions of selenite over several weeks. The exact dosing schedule was based on previous research. The treatment was given under compassionate use because the patient had exhausted standard options. Imaging after treatment showed no detectable tumors.

What are the next steps for selenite research?

Researchers plan to conduct larger clinical trials to evaluate selenite’s safety and effectiveness in lung cancer and other cancers. The case report provides a rationale for such studies but does not replace the need for rigorous testing. Patients should not seek selenite treatment outside of clinical trials due to potential toxicity.

This is an original report by Vital Signs Today, informed by reporting from Medical Xpress. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.